Pancragen vs Vilon
Moderate Research vs Moderate Research
compatible Part of Khavinson bioregulator family; targets different tissue.
Molecular Data
Pancragen Vilon
Weight 576 Da 275 Da
Half-life Not established Not established
Chain 4 amino acids 2 amino acids
Type Tetrapeptide bioregulator Dipeptide bioregulator
Key Benefits
Pancragen
01 Corrects impaired glucose tolerance
02 Normalizes insulin levels
03 Normalizes C-peptide levels
04 Improves endocrine pancreatic function
05 Supports pancreatic cell differentiation
06 Regulates melatonin expression
07 Reduces metabolic syndrome incidence
08 Upregulates key pancreatic transcription factors
Vilon
01 Increases mean lifespan 20-40% in animal models
02 Suppresses tumor development
03 Stimulates thymocyte proliferation
04 Activates T-helper cells
05 Restores chromatin structure in aged lymphocytes
06 Enhances intestinal barrier function
07 Improves enzyme activity in aged tissue
08 Part of comprehensive longevity protocols
Dosing Protocols
Pancragen
10-20mg daily / Daily for 10-20 days per cycle
Research protocol 0.05 mg/kg Daily for 10 days
Vilon
10-20 mg per day (oral capsules) or 10 mg (injectable) / Daily for 10-20 consecutive days (Khavinson bioregulator cycle)
Research protocol 10 mg Daily for 10 days
Side Effects
Pancragen
Generally well-tolerated
Minimal side effects reported
Vilon
Generally well-tolerated
Minimal side effects reported
Contraindications
Active pancreatic emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Type 1 diabetes (consult physician)
Active autoimmune flares (consult physician)
Known hypersensitivity
Pregnancy or breastfeeding
Research Evidence
Pancragen Vilon
Status Moderate Research Moderate Research
References 4 studies 4 studies
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.